Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› California
Clinical trial register · United States · industry-sponsored

Clinical Trials in California, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9122 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 07 Oct 2026, 03:16 UTC
9122
Studies in scope
industry-sponsored, all four open statuses
4946
Recruiting now
open to new participants
2190
Lead sponsors
across recruiting studies
Top states
California 45 Florida 37 Georgia 32 Colorado 23 Connecticut 20
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca232 Eli Lilly and Company151 AbbVie145 Merck Sharp & Dohme LLC128 Pfizer114 Clear sponsor filter
State
California45 Florida37 Georgia32 Colorado23 Connecticut20
All 42 states
Target enrolment
to

Trials with a site in California

45 of 9122 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer
NCT07806773NSCLC, Non Small Cell Lung Cancer
DrugTUB-040
Gilead Sciences
Phase 2
80
California, New Jersey
2026-11
Not yet open
Study of TUB-040 in Patients With Recurrent or Progressive Uterine Cancer After Chemotherapy and Immune Therapy
NCT07743541Uterine Endometrial Cancer
Gilead Sciences
Phase 1/2
100
California, New Jersey, New York, Utah
2026-10
Recruiting
Study of GS-0415 and How It Works in People With HIV
NCT07719491HIV -1 Infection
Gilead Sciences
Phase 1
112
California, District of Columbia, Florida, Georgia, Indiana, Massachusetts, Nevada, New Jersey
2026-07-22
Recruiting
Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy
NCT07682961HIV Infections
DrugsTeropavimab·Zinlirvimab·Rilpivirine·Cabotegravir
Gilead Sciences
Phase 3
590
California, Florida, Georgia, Michigan, Missouri, Texas, Virginia, Washington
2026-07-14
Recruiting
A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1
NCT07645287HIV-1-infection
DrugsGS-3242·B/F/TAF·Lenacapavir
Gilead Sciences
Phase 2
175
Arizona, California, Colorado, Florida, Georgia, Michigan, Missouri, New Jersey
2026-06-15
Recruiting
Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer
NCT07736937Ovarian Cancer
DrugsTUB-040·Carbo
Gilead Sciences
Phase 1/2
72
California, New Jersey, New York
2026-03-30
Recruiting
Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention
NCT07473778HIV Infections
DrugsF/TAF·Emtricitabine/tenofovir disoproxil fumarate·Descovy·F/TDF
Gilead Sciences
Observational
3,000
Alabama, California, Colorado, Florida, Georgia, Illinois, Louisiana, Maryland
2026-03-17
Active, closed
Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIV
NCT07055451HIV-1-infection
DrugB/F/TAF
Gilead Sciences
Phase 1
16
California, Georgia, Tennessee
2025-08-12
Recruiting
Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus
NCT07096193Chronic Hepatitis Delta
Gilead Sciences
Phase 1/2
200
California, Kentucky, Maryland, New York
2025-07-31
Active, closed
Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)
NCT07047716HIV Pre-exposure Prophylaxis
DrugLenacapavir
Gilead Sciences
Phase 3
339
Alabama, California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Louisiana
2025-07-22
Active, closed
Study of GS-0151 in Participants With Rheumatoid Arthritis
NCT06902519Rheumatoid Arthritis
Gilead Sciences
Phase 1
65
Alabama, California, Florida, Illinois, Louisiana, Oklahoma, Pennsylvania, Texas
2025-05-14
Recruiting
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
NCT06926920Triple Negative Breast Cancer
DrugSacituzumab Govitecan
Gilead Sciences
Phase 1/2
100
California, Georgia, Kansas, Missouri, Tennessee, Texas, Virginia
2025-04-30
Recruiting
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
NCT06801834Extensive Stage Small Cell Lung Cancer (ES-SCLC)
DrugsAmrubicin·Lurbinectedin·Topotecan·Sacituzumab Govitecan
Gilead Sciences
Phase 3
695
Alaska, Arkansas, California, Florida, Illinois, Indiana, Kentucky, Maine
2025-04-04
Active, closed
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1
NCT06630286HIV-1-infection
DrugsISL/LEN·B/F/TAF
Gilead Sciences
Phase 3
609
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2024-10-09
Active, closed
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1
NCT06630299HIV-1-Infection
DrugsAntiretroviral Combinations·ISL/LEN
Gilead Sciences
Phase 3
600
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2024-10-08
Active, closed
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
NCT06486441Endometrial Cancer
DrugsAdriamycin·Sacituzumab Govitecan·Taxol·Doxorubicin
Gilead Sciences
Phase 3
640
Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2024-08-28
Active, closed
Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed
NCT06544733HIV-1-Infection
DrugB/F/TAF
Gilead Sciences
Phase 2/3
675
Alabama, California, District of Columbia, Florida, Georgia, Michigan, Missouri, New Jersey
2024-08-20
Recruiting
Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors
NCT06532565Advanced Solid Tumors
DrugZimberelimab
Gilead Sciences
Phase 1
154
California, Massachusetts, Texas, Virginia
2024-07-26
Active, closed
Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06290934Ulcerative Colitis
Gilead Sciences
Phase 2
228
Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky, Louisiana
2024-03-27
Active, closed
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy
NCT06333808HIV-1-infection
DrugsBictegravir·B/F/TAF·Lenacapavir
Gilead Sciences
Phase 3
577
Arizona, California, Colorado, Connecticut, Florida, Georgia, Massachusetts, Michigan
2024-03-25
Active, closed
Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)
NCT06101342Pre-Exposure Prophylaxis of HIV Infection
DrugsEmtricitabine/tenofovir disoproxil fumarate·F/TDF·Lenacapavir
Gilead Sciences
Phase 2
181
California, Florida, Maryland, New Jersey, New York, Pennsylvania, Texas, West Virginia
2023-12-13
Active, closed
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06029972Ulcerative Colitis
Gilead Sciences
Phase 2
176
Arizona, California, Florida, Michigan, Minnesota, Mississippi, Missouri, New York
2023-12-05
Active, closed
Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)
NCT06101329Pre-Exposure Prophylaxis of HIV Infection
DrugsEmtricitabine/tenofovir disoproxil fumarate·F/TDF·Lenacapavir
Gilead Sciences
Phase 2
253
Alabama, California, District of Columbia, Georgia, Massachusetts, New Jersey, New York, North Carolina
2023-11-17
Recruiting
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
NCT06051617Primary Biliary Cholangitis
DrugSeladelpar
Gilead Sciences
Phase 3
402
Alabama, Arizona, California, Florida, Georgia, Illinois, Iowa, Kentucky
2023-09-07
Active, closed
A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection
NCT05729568HIV-1 Infection
DrugsTeropavimab·Zinlirvimab·Lenacapavir
Gilead Sciences
Phase 2
83
California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Missouri, New Mexico
2023-05-15
Active, closed
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
NCT05840211Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer
DrugsAbraxane·Xeloda·Sacituzumab Govitecan·Taxol
Gilead Sciences
Phase 3
654
Arizona, California, Colorado, Connecticut, Florida, Georgia, Kansas, Louisiana
2023-05-08
Active, closed
Study With Various Immunotherapy Treatments in Participants With Lung Cancer
NCT05676931Advanced Non-Small Cell Lung Cancer
DrugsQuemliclustat·Domvanalimab·Zimberelimab·Docetaxel
Gilead Sciences
Phase 2
400
Alabama, California, Florida, Illinois, Louisiana, Michigan, Virginia, Washington
2023-02-21
Recruiting
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
NCT05633654Triple Negative Breast Cancer
DrugsXeloda·Sacituzumab Govitecan·Keytruda·Capecitabine
Gilead Sciences
Phase 3
1,514
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2022-12-12
Active, closed
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
NCT05502237Non-small Cell Lung Cancer
DrugsDomvanalimab·Zimberelimab·Nab-paclitaxel·Pemetrexed
Gilead Sciences
Phase 3
1,021
California, District of Columbia, Florida, Illinois, North Carolina, Ohio, Oregon, Pennsylvania
2022-10-12
Active, closed
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen
NCT05502341HIV-1-infection
DrugsBictegravir·Lenacapavir
Gilead Sciences
Phase 2/3
689
California, Colorado, Connecticut, Florida, Georgia, Illinois, Missouri, New Jersey
2022-08-16
Active, closed
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382286Triple Negative Breast Cancer, PD-L1 Positive
DrugsAbraxane·Sacituzumab Govitecan·Taxol·Nab-paclitaxel
Gilead Sciences
Phase 3
443
Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2022-07-25
Active, closed
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382299Triple Negative Breast Cancer, PD-L1 Negative
DrugsAbraxane·Sacituzumab Govitecan·Nab-paclitaxel·Gemcitabine
Gilead Sciences
Phase 3
623
Arizona, California, Colorado, Florida, Georgia, Illinois, Iowa, Kentucky
2022-07-20
Active, closed
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
NCT05186974Non-small Cell Lung Cancer
DrugsSacituzumab Govitecan·Paraplatin·Keytruda·Cisplatin
Gilead Sciences
Phase 2
193
Alaska, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Kansas
2022-05-30
Active, closed
Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT05089734Non-Small Cell Lung Cancer
DrugsSacituzumab Govitecan·Docetaxel
Gilead Sciences
Phase 3
603
Alaska, Arizona, California, Colorado, Florida, Illinois, Iowa, Kansas
2021-11-17
Active, closed
Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV
NCT05052996HIV-1 Infection
DrugsB/F/TAF·Lenacapavir
Gilead Sciences
Phase 2
142
California, Colorado, District of Columbia, Florida, Georgia, Hawaii, Illinois, Indiana
2021-10-05
Active, closed
Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors
NCT05007782Advanced Solid Tumor
DrugsDenikitug·Zimberelimab
Gilead Sciences
Phase 1
304
California, Connecticut, Massachusetts, Tennessee, Texas, Wisconsin
2021-08-18
Active, closed
Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV Infection
NCT04925752Pre-Exposure Prophylaxis of HIV Infection
DrugsF/TAF·Descovy·F/TDF·Lenacapavir
Gilead Sciences
Phase 3
3,292
Alabama, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2021-06-28
Recruiting
Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
NCT04617522Advanced or Metastatic Solid Tumor, Liver Failure
DrugSacituzumab Govitecan
Gilead Sciences
Phase 1
30
California, Delaware, Maryland, Texas
2021-04-06
Active, closed
Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance
NCT04150068HIV-1-infection
DrugLenacapavir
Gilead Sciences
Phase 2/3
72
California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Michigan, Missouri
2019-11-21
Active, closed
Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors
NCT03964727Metastatic Solid Tumor
DrugSacituzumab Govitecan
Gilead Sciences
Phase 2
227
Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Illinois, Indiana
2019-10-15
Active, closed
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
NCT03547973Metastatic Urothelial Cancer
DrugsDomvanalimab·Zimberelimab·Avelumab·Enfortumab Vedotin
Gilead Sciences
Phase 2
502
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Kentucky
2018-08-13
Active, closed
Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)
NCT03301506Primary Biliary Cirrhosis
DrugSeladelpar
Gilead Sciences
Phase 3
340
Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois, Louisiana
2017-12-12
Active, closed
Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection
NCT02932150Chronic Hepatitis B
Gilead Sciences
Phase 2
150
California, Colorado, Indiana, Maryland, Missouri, New York, Ohio, Tennessee
2016-11
Active, closed
Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV
NCT02016924Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
DrugsCobicistat·F/TAF·LPV/r·Descovy
Gilead Sciences
Phase 2/3
133
California, Colorado, District of Columbia, Florida, Tennessee, Texas
2014-01-16
Active, closed
Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection
NCT01651403Chronic Hepatitis B
DrugTenofovir DF
Gilead Sciences
Phase 3
90
Arizona, California, Colorado, Ohio, Texas
2012-12-06
Rows per page Showing 1–45 of 45
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 7 October 2026. https://priyalifescience.com/clinical-trials-usa/state/california

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,122 studies in total at the last sync on 07 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 45 of those studies with a site in California that also match the filters currently applied.

How many clinical trials are recruiting in California?

12 of the 45 studies on this page are recruiting new participants as of the 07 Oct 2026, 03:16 UTC sync. A further 2 have not yet opened recruitment, 31 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (California), 45 studies
PhaseStudiesRecruitingShare
Phase 317437.8%
Phase 213128.9%
Phase 16313.3%
Phase 1/2438.9%
Phase 2/3408.9%
Observational112.2%

Most active sponsors

Lead sponsors with the most studies (California)
Lead sponsorStudiesRecruiting
Gilead Sciences4512
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.